跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
CAR-TG
首页
药物
CAR-TG
CAR-TG
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
ANTI-HER2 CAR NK CELLS, METHODS OF THEIR PRODUCTION AND USES THEREOF
US 20240335472 A1
申请人: GAMIDA CELL LTD
优先权: 2021
CN
US
2 件公开
T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase
US 7381401 B2
申请人: UNIV CHICAGO
优先权: 2005
US
shRNA靶向抑制CD38的抗CD38 CAR分子及其药物
CN 116656743 B
申请人: 深圳细胞谷生物医药有限公司
优先权: 2023
CN
ShRNA (short hairpin ribonucleic acid) for targeted inhibition of PTPN2 (protein tyrosine phosphatase N2) as well as CAR-T cell and pharmaceutical composition comprising shRNA
CN 118562802 A
申请人: SHENZHEN CELL VALLEY BIOMEDICAL CO LTD
优先权: 2024
CN
Application of toxoplasma gondii gene deletion strain for expressing tumor specific antigen receptor in preparation of anti-tumor biological preparation
CN 120939221 A
申请人: HANGZHOU MEDICAL COLLEGE
优先权: 2025
CN
药物
反馈